{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:37:03Z","timestamp":1769560623647,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["KAW 2021.0010_VC-2020-0040"],"award-info":[{"award-number":["KAW 2021.0010_VC-2020-0040"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-05450"],"award-info":[{"award-number":["2021-05450"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-03118"],"award-info":[{"award-number":["2021-03118"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016408","name":"G\u00f6ran Gustafsson Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016408","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.<\/jats:p>","DOI":"10.1038\/s41541-024-00829-9","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T16:03:19Z","timestamp":1708617799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-3330","authenticated-orcid":false,"given":"Ahmet","family":"Yalcinkaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5973-9637","authenticated-orcid":false,"given":"Axel","family":"Cederholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0050-704X","authenticated-orcid":false,"given":"Maribel","family":"Aranda-Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2424-3475","authenticated-orcid":false,"given":"Anish","family":"Behere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6636-2008","authenticated-orcid":false,"given":"Hedvig","family":"Mildner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7256-5770","authenticated-orcid":false,"given":"Tadepally","family":"Lakshmikanth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin Habimana","family":"Mugabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olov","family":"Ekwall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6091-9914","authenticated-orcid":false,"given":"Olle","family":"K\u00e4mpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Bensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petter","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4r","family":"Hallberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6368-2622","authenticated-orcid":false,"given":"Mia","family":"Wadelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Landegren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"829_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-022-01247-x","volume":"23","author":"A Chatterjee","year":"2023","unstructured":"Chatterjee, A. & Chakravarty, A. Neurological complications following COVID-19 vaccination. Curr. Neurol. Neurosci. Rep. 23, 1\u201314 (2023).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"829_CR2","doi-asserted-by":"publisher","unstructured":"Rabail, R. et al. The side effects and adverse clinical cases reported after COVID-19 immunization. Vaccines 10, https:\/\/doi.org\/10.3390\/vaccines10040488 (2022).","DOI":"10.3390\/vaccines10040488"},{"key":"829_CR3","doi-asserted-by":"publisher","unstructured":"Lamprinou, M., Sachinidis, A., Stamoula, E., Vavilis, T. & Papazisis, G. COVID-19 vaccines adverse events: Potential molecular mechanisms. Immunologic Research, https:\/\/doi.org\/10.1007\/s12026-023-09357-5 (2023).","DOI":"10.1007\/s12026-023-09357-5"},{"key":"829_CR4","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz, N. H. et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 384, 2124\u20132130 (2021).","journal-title":"N. Engl. J. Med."},{"key":"829_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41577-020-00429-3","volume":"20","author":"JS Lee","year":"2020","unstructured":"Lee, J. S. & Shin, E.-C. The type I interferon response in COVID-19: Implications for treatment. Nat. Rev. Immunol. 20, 585\u2013586 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"829_CR6","doi-asserted-by":"publisher","unstructured":"Zhang, Q. et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J. Exp. Med. 219, https:\/\/doi.org\/10.1084\/jem.20220514 (2022).","DOI":"10.1084\/jem.20220514"},{"key":"829_CR7","doi-asserted-by":"publisher","unstructured":"Gervais, A. et al. Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in \u223c40% of patients. J. Exp. Med. 220, https:\/\/doi.org\/10.1084\/jem.20230661 (2023).","DOI":"10.1084\/jem.20230661"},{"key":"829_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijid.2023.03.011","volume":"130","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis. Int. J. Infect. Dis. 130, 147\u2013152 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"829_CR9","doi-asserted-by":"publisher","first-page":"eabl4340","DOI":"10.1126\/sciimmunol.abl4340","volume":"6","author":"P Bastard","year":"2021","unstructured":"Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021).","journal-title":"Sci. Immunol."},{"key":"829_CR10","doi-asserted-by":"publisher","unstructured":"Bastard, P. et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. 218, https:\/\/doi.org\/10.1084\/jem.20202486 (2021).","DOI":"10.1084\/jem.20202486"},{"key":"829_CR11","doi-asserted-by":"publisher","unstructured":"Pomara, C. et al. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis. Diagnostics (Basel) 11, https:\/\/doi.org\/10.3390\/diagnostics11060955 (2021).","DOI":"10.3390\/diagnostics11060955"},{"key":"829_CR12","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","volume":"3","author":"A Meager","year":"2006","unstructured":"Meager, A. et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3, e289 (2006).","journal-title":"PLoS Med."},{"key":"829_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jaci.2021.03.034","volume":"148","author":"A Lemarquis","year":"2021","unstructured":"Lemarquis, A. et al. Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis. J. Allergy Clin. Immunol. 148, 96\u201398 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"829_CR14","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).","journal-title":"Science"},{"key":"829_CR15","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3389\/fmicb.2020.01526","volume":"11","author":"CMC Rodrigues","year":"2020","unstructured":"Rodrigues, C. M. C. & Plotkin, S. A. Impact of vaccines; health, economic and social perspectives. Front. Microbiol. 11, 1526 (2020).","journal-title":"Front. Microbiol."},{"key":"829_CR16","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMc2205667","volume":"387","author":"L Thurner","year":"2022","unstructured":"Thurner, L. et al. IL-1RA antibodies in myocarditis after SARS-CoV-2 vaccination. N. Engl. J. Med. 387, 1524\u20131527 (2022).","journal-title":"N. Engl. J. Med."},{"key":"829_CR17","doi-asserted-by":"publisher","unstructured":"McKean, N. & Chircop, C. Guillain-Barr\u00e9 syndrome after COVID-19 vaccination. BMJ Case Rep. 14, https:\/\/doi.org\/10.1136\/bcr-2021-244125 (2021).","DOI":"10.1136\/bcr-2021-244125"},{"key":"829_CR18","doi-asserted-by":"publisher","unstructured":"Gao, J. J. et al. Acute transverse myelitis following COVID-19 vaccination. Vaccines 9, https:\/\/doi.org\/10.3390\/vaccines9091008 (2021).","DOI":"10.3390\/vaccines9091008"},{"key":"829_CR19","doi-asserted-by":"publisher","unstructured":"Kounis, N. G. et al. Allergic reactions to current available COVID-19 vaccinations: Pathophysiology, causality, and therapeutic considerations. Vaccines 9, https:\/\/doi.org\/10.3390\/vaccines9030221 (2021).","DOI":"10.3390\/vaccines9030221"},{"key":"829_CR20","doi-asserted-by":"publisher","unstructured":"Sokal, A. et al. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. J. Exp. Med. 220, https:\/\/doi.org\/10.1084\/jem.20220258 (2023).","DOI":"10.1084\/jem.20220258"},{"key":"829_CR21","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","volume":"384","author":"M Scully","year":"2021","unstructured":"Scully, M. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384, 2202\u20132211 (2021).","journal-title":"N. Engl. J. Med."},{"key":"829_CR22","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMc2105869","volume":"384","author":"K-L Muir","year":"2021","unstructured":"Muir, K.-L., Kallam, A., Koepsell, S. A. & Gundabolu, K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N. Engl. J. Med. 384, 1964\u20131965 (2021).","journal-title":"N. Engl. J. Med"},{"key":"829_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-022-01095-5","volume":"12","author":"R Arrestier","year":"2022","unstructured":"Arrestier, R. et al. Auto-antibodies against type I IFNs in\u2009>\u200910% of critically ill COVID-19 patients: a prospective multicentre study. Ann. Intensive Care 12, 121 (2022).","journal-title":"Ann. Intensive Care"},{"key":"829_CR24","unstructured":"R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, 2023)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00829-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00829-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00829-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T16:08:52Z","timestamp":1708618132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00829-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00829-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"13 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}